摘要
目的比较恶唑烷酮类抗生素利奈唑胺与糖肽类抗生素万古霉素治疗老年耐甲氧西林金黄色葡萄球菌(MRSA)感染性心内膜炎的临床疗效及安全性。方法 2008年5月至2010年5月,我院收治59例老年耐甲氧西林金黄色葡萄球菌(MRSA)感染性心内膜炎患者,其中33例接受利奈唑胺治疗,26例接受万古霉素治疗,分别对临床治愈率、细菌清除率及不良反应发生率等进行比较。结果两组治疗前临床情况无明显统计学差异。利奈唑胺组治愈率72.73%,细菌清除率84.85%,不良反应发生率21.21%;万古霉素组治愈率34.62%,细菌清除率38.46%,不良反应发生率65.38%。结论利奈唑胺组治疗老年MRSA肺炎临床疗效优于万古霉素组,不良反应少于万古霉素组,临床上药物治疗老年MRSA感染性心内膜炎可优先考虑利奈唑胺。
OBJECTIVE To compare the clinical therapeutics and medication safety of Linezolid and Vancomytin in gerontat-patients with MRSA-related infective endocardits. METHODS A total of 59 gerontal-patients with MRSA-related infective endocardits from May 2008 to May 2010 were included in this study and compared the cure rate ,bacterium clearance rate and adverse-effect incidence rate in Linezolid group （include 33 patients） and Vancomycin group （include 26 patients） were compared. RESULTS Two groups were similar in their demographics and preoperative clinical characteristics. Linezolid group ：cure rate was 72.73% ,bacterium clearance rate was 84. 85%, adverse-effect incidence rate was 21.21% ;Vancomycin group：cure rate was 34. 62%, bacterium clearance rate was 38.46% ,adverse-effect incidence rate was 65.38%. CONCLUSION Compared with Vancomycin, Linezolid has advantages in therapeutics-choice and safety-concern for gerontal-patients with MRSA-related infective endoeardits.
出处
《海峡药学》
2013年第11期102-103,共2页
Strait Pharmaceutical Journal
